Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
01:41pm, Thursday, 01'st Feb 2024
Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance.
Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript
01:18pm, Thursday, 01'st Feb 2024
Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript
Merck (MRK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
11:31am, Thursday, 01'st Feb 2024
The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Bulls Pick Up Merck Stock After Surprise Quarterly Win
10:59am, Thursday, 01'st Feb 2024
Merck & Co Inc (NYSE:MRK) announced surprise fourth-quarter profits of 3 cents per share earlier, as well as revenue of $14.63 billion, both of which easily surpassed analysts' expectations.
Merck (MRK) Beats Q4 Earnings Estimates
08:46am, Thursday, 01'st Feb 2024
Merck (MRK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $1.62 per share a year ago.
Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
08:09am, Thursday, 01'st Feb 2024
CNBC's Mike Santoli reports on the company's quarterly earnings results.
Merck Stock Jumps as Earnings Beat, Guidance Ahead of Wall Street Expectations
06:46am, Thursday, 01'st Feb 2024
Merck posted a 3-cent a share loss on revenue of $14.6 billion in the fourth quarter. Analysts surveyed by FactSet had expected Merck to report an 11-cent loss on revenue of $14.5 billion.
Merck posts better-than-expected quarterly results on soaring Keytruda sales
06:33am, Thursday, 01'st Feb 2024
Merck & Co on Thursday reported better-than-expected fourth-quarter results on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine.
Merck's fourth-quarter results top estimates, fueled by key cancer drugs and vaccines
06:32am, Thursday, 01'st Feb 2024
Merck & Co. Inc. on Thursday reported fourth-quarter earnings and sales that beat analysts' expectations, powered by strong growth in cancer and vaccine products.
Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
06:31am, Thursday, 01'st Feb 2024
Merck still posted a quarterly loss due to previously announced charges associated with its cancer drug collaboration deal with Daiichi Sankyo.
IBM, Verizon, Merck stocks lead Dow to new highs
08:31am, Wednesday, 31'st Jan 2024
You don't hear as much about the Dow Jones Industrial Average as investors did a few decades ago, as the broad consensus has deemed the S&P 500 a better indicator of market conditions.
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
01:52pm, Tuesday, 30'th Jan 2024
J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
12:56pm, Monday, 29'th Jan 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
Pharma industry to get US government price cut proposals by Thursday
11:35am, Monday, 29'th Jan 2024
Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
09:45am, Sunday, 28'th Jan 2024
Merck is well on its way to replacing its most important growth driver. Fiverr will continue to benefit from the expanding gig economy.
